News
Bhekisisa: 180 000 infections in 2024, 47 000 by 2045 — if South Africa rolls out the twice-a-year HIV prevention jab fast enough
8+ hour, 42+ min ago (219+ words) " South Africa will receive its first batch of the once-every-six-months HIV prevention shot, lenacapavir, soon. Roll-out in government clinics is set to start within the next couple of months, the health department says " depending on when the first batch of…...
[Press release] LSHTM: Community-based integrated care for HIV, diabetes and hypertension safely expands access while easing pressure on health facilities in sub-Saharan Africa
2+ day, 9+ hour ago (224+ words) [Press release] LSHTM: Community-based integrated care for HIV, diabetes and hypertension safely expands access while easing pressure on health facilities in sub-Saharan Africa'European AIDS Treatment Group [Press release] LSHTM: Community-based integrated care for HIV, diabetes and hypertension safely expands access…...
[CROI 2026] aidsmap: African paediatric studies at CROI: HIV remission in children, three bNAbs in babies, two years on injectables in teens
2+ week, 4+ hour ago (220+ words) [CROI 2026] aidsmap: African paediatric studies at CROI: HIV remission in children, three bNAbs in babies, two years on injectables in teens'European AIDS Treatment Group [CROI 2026] aidsmap: African paediatric studies at CROI: HIV remission in children, three bNAbs in babies, two…...
[Joint press release] South Africa launches bid to enable local production of long-acting HIV prevention drug, lenacapavir
2+ week, 1+ day ago (226+ words) [Joint press release] South Africa launches bid to enable local production of long-acting HIV prevention drug, lenacapavir'European AIDS Treatment Group [Joint press release] South Africa launches bid to enable local production of long-acting HIV prevention drug, lenacapavir 5 March 2026 " The Government…...
[CROI 2026] [Press release] ViiV Healthcare reports long-acting injectable Cabenuva effectively maintains viral suppression in adolescents living with HIV, with >97% preferring injections over daily oral treatment
3+ week, 3+ day ago (111+ words) ViiV Healthcare announced week 96 and end'of'study results from the phase I/II IMPAACT 2017 (MOCHA) study, the first trial to evaluate a complete injectable long'acting treatment regimen in adolescents living with HIV. Results showed 94.4% of virologically suppressed adolescents aged 12 to 97% indicating…...
Devex: Where is HIV prevention drug lenacapavir in ‘America First’ health deals?
1+ mon, 1+ week ago (125+ words) The Trump administration's'America First" global health strategy proudly showcases lenacapavir, a twice-yearly injectable for HIV prevention, as proof of US innovation and leadership. Yet in practice, $11 billion in US health aidis now flowing through 15bilateral agreements that fail to include a…...
Devex: One year after US aid freeze, HIV care in Africa is in retreat
1+ mon, 3+ week ago (124+ words) Devex: One year after US aid freeze, HIV care in Africa is in retreat'European AIDS Treatment Group Devex: One year after US aid freeze, HIV care in Africa is in retreat Related HIV and Co-Infections News Bioengineering: Overcoming barriers: Access…...
[Press release] Unitaid approves new investments to accelerate equitable access to lenacapavir for HIV prevention
2+ mon, 1+ week ago (208+ words) [Press release] Unitaid approves new investments to accelerate equitable access to lenacapavir for HIV prevention'European AIDS Treatment Group [Press release] Unitaid approves new investments to accelerate equitable access to lenacapavir for HIV prevention In December 2025, Unitaid approved an additional US…...
[Press release] IAVI announces first vaccinations in IAVI G004, a Phase 1 clinical trial of a promising HIV vaccine approach
2+ mon, 1+ week ago (268+ words) [Press release] IAVI announces first vaccinations in IAVI G004, a Phase 1 clinical trial of a promising HIV vaccine approach'European AIDS Treatment Group [Press release] IAVI announces first vaccinations in IAVI G004, a Phase 1 clinical trial of a promising HIV vaccine approach Study…...